Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy

INTRODUCTION: Mutations (MT) of the KRAS gene are the most common mutation in non-small cell lung cancer (NSCLC), seen in about 20–25% of all adenocarcinomas. Effect of KRAS MT on response to cytotoxic chemotherapy is unclear. METHODS: We undertook a single-institution retrospective analysis of 93 c...

Descripción completa

Detalles Bibliográficos
Autores principales: Brady, Anna K., McNeill, Jonathan D., Judy, Brendan, Bauml, Joshua, Evans, Tracey L., Cohen, Roger B., Langer, Corey, Vachani, Anil, Aggarwal, Charu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745798/
https://www.ncbi.nlm.nih.gov/pubmed/26471290

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745798/
https://www.ncbi.nlm.nih.gov/pubmed/26471290

Ejemplares similares